Pharmacodynamics and pharmacokinetics of miloxicam in the horse.

This research article evaluated the anti-inflammatory drug miloxicam in horses. The authors studied how the drug affects inflammation and how it is transported and processed in the bodies of horses.

Research Design

• In this two-part cross-over study, six New Forest ponies were injected with miloxicam, while three were given a placebo.
• Through a carrageenan-sponge model, the researchers observed the reactions to acute inflammation for both the treated and untreated ponies.

Outcomes

• The researchers noted that the increase in skin temperature over the inflammation site was less in ponies administered the drug, but the differences were not statistically significant.
• The concentrations of enzymes, acid phosphatase (AP) and lysozyme, in the inflammatory exudate (fluid oozing out of infected tissues) were not significantly different between drug-treated ponies and those receiving placebo.
• However, other parameters such as concentration of protein, lactate dehydrogenase (LDH), and leucocyte (white blood cell) numbers in infected fluid were significantly lowered in ponies that received the drug, when data from all sampling times were pooled.
• Again, these differences were not significant when observed at individual sampling times.
• Exudate concentrations of eicosanoids (mediators of inflammation and immunity) such as bicyclic-PGE2, 6-keto-PGF1 alpha, and TXB2 were significantly reduced by miloxicam at most sampling times, and serum TXB2 was also significantly reduced at the 4th and 8th hours after drug administration.
• However, the concentration of miloxicam in the exudate was initially similar to, and eventually exceeded, that in the plasma, which may explain the more prolonged inhibition of eicosanoid synthesis in the exudate than in the serum.

Pharmacokinetics of Miloxicam

• The study found that the plasma concentration-time curve was defined by a three-compartment open model in one pony and by a two-compartment model in five ponies. These models describe how the drug is absorbed, distributed, metabolized, and excreted in the body, helping to predict how the drug behaves over time.
• The average values for pharmacokinetic parameters among the five ponies were as follows: t1/2 alpha (the half-life of distribution) was 0.40 hours, t1/2 beta (the half-life of elimination) was 2.70 hours, Vd area (volume of distribution) was 0.158 l/kg, and ClB (clearance rate from the body) was 41.87 ml/kg/h.

The findings of this study highlight the importance of conducting a single experimental study that explores both the pharmacodynamics (how the drug affects the body) and pharmacokinetics (how the body processes the drug) in order to fully understand a drug’s potential and efficacy in treating specific health conditions.